EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

CRISPR-Cas Systems in the Fight Against Antimicrobial Resistance: Current Status, Potentials, and Future Directions

Mohamed Mustaf Ahmed iD, Hassan Hakeem Kayode iD, Olalekan John Okesanya iD, Bonaventure Michael Ukoaka iD, Gilbert Eshun iD, Marina Ramzy Mourid iD, Olaniyi Abideen Adigun iD, Jerico Bautista Ogaya iD, Zeinab Omar Mohamed iD, Don Eliseo Lucero-Prisno iD

Infection and Drug Resistance · 2024-11 · Volume 17 · 5229-5245

DOI: 10.2147/idr.s494327 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Infection and Drug Resistance, 2024-11. Verfasst von Mohamed Mustaf Ahmed und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Sciences, SIMAD University, Mogadishu, Somalia. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antimicrobial resistance (AMR) is a critical global health concern that threatens the efficacy of existing antibiotics and poses significant challenges to public health and the economy worldwide. This review explores the potential of CRISPR-Cas systems as a novel approach to combating AMR and examines current applications, limitations, and prospects.

Methods

A comprehensive literature search was conducted across multiple databases, including PubMed, Google Scholar, Scopus, and Web of Science, covering publications published from 2014 to August 2024. This review focuses on CRISPR-Cas technologies and their applications in AMR.

Results

CRISPR-Cas systems have demonstrated efficacy in combating antimicrobial resistance by targeting and eliminating antibiotic-resistance genes. For example, studies have shown that CRISPR-Cas9 can effectively target and eliminate colistin resistance genes in MCR-1 plasmids, restoring susceptibility to carbapenems in bacteria such as E. coli and Klebsiella pneumoniae. Further molecular findings highlight the impact of CRISPR-Cas systems on various bacterial species, such as Enterococcus faecalis, in which CRISPR systems play a crucial role in preventing the acquisition of resistance genes. The effectiveness of CRISPR-Cas in targeting these genes varies due to differences in CRISPR locus formation among bacterial species. For instance, variations in CRISPR loci influence the targeting of resistance genes in E. faecalis, and CRISPR-Cas9 successfully reduces resistance by targeting genes such as tetM and ermB.

Conclusion

CRISPR-Cas systems are promising for fighting AMR by targeting and eliminating antibiotic-resistant genes, as demonstrated by the effective targeting of colistin resistance genes on MCR-1 plasmids and their similar activities. However, the effectiveness of CRISPR-Cas is affected by variations in the CRISPR loci among bacterial species. Challenges persist, such as optimizing delivery methods and addressing off-target effects to ensure the safety and precision of CRISPR-Cas systems in clinical settings.

Schlagwörter

Stichwörter der Autor:innen

CRISPR-Cas systemsantimicrobial resistancebacteriophage deliverygene editing

Autor:innen und Institutionen

  • Faculty of Medicine and Health Sciences, SIMAD University, Mogadishu, Somalia.
  • Institute for Global Health, SIMAD University, Mogadishu, Somalia.
  • Department of Medical Laboratory Science, Oyo State Hospital Management Board, Oyo, Nigeria.
  • Faculty of Medicine, Department of Public Health and Maritime Transport, University of Thessaly, Volos, Greece.
  • Community and Clinical Research Division, First on-Call Initiative, Port Harcourt, Nigeria.
  • Department of Medicine, Seventh Day Adventist Hospital, Asamang, Ghana.

ORCID-Profile: Mohamed Mustaf Ahmed, Hassan Hakeem Kayode, Olalekan John Okesanya, Bonaventure Michael Ukoaka, Gilbert Eshun, Marina Ramzy Mourid, Olaniyi Abideen Adigun, Jerico Bautista Ogaya, Zeinab Omar Mohamed, Don Eliseo Lucero-Prisno

Zitieren

APA

Ahmed, M. M., Kayode, H. H., Okesanya, O. J., Ukoaka, B. M., Eshun, G., Mourid, M. R., Adigun, O. A., Ogaya, J. B., Mohamed, Z. O., & Lucero-Prisno, D. E. (2024). CRISPR-Cas Systems in the Fight Against Antimicrobial Resistance: Current Status, Potentials, and Future Directions. Infection and Drug Resistance, Volume 17, 5229-5245. https://doi.org/10.2147/idr.s494327

Vancouver

Ahmed MM, Kayode HH, Okesanya OJ, Ukoaka BM, Eshun G, Mourid MR, et al. CRISPR-Cas Systems in the Fight Against Antimicrobial Resistance: Current Status, Potentials, and Future Directions. Infection and Drug Resistance. 2024;Volume 17:5229-5245. doi:10.2147/idr.s494327

BibTeX
@article{Ahmed2024,
  author = {Ahmed, Mohamed Mustaf and Kayode, Hassan Hakeem and Okesanya, Olalekan John and Ukoaka, Bonaventure Michael and Eshun, Gilbert and Mourid, Marina Ramzy and Adigun, Olaniyi Abideen and Ogaya, Jerico Bautista and Mohamed, Zeinab Omar and Lucero-Prisno, Don Eliseo},
  title = {CRISPR-Cas Systems in the Fight Against Antimicrobial Resistance: Current Status, Potentials, and Future Directions},
  journal = {Infection and Drug Resistance},
  year = {2024},
  volume = {Volume 17},
  pages = {5229--5245},
  doi = {10.2147/idr.s494327}
}
Kostenlos starten →